Article
The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease.
Leukemia & lymphoma - 1 Jul 2012
Best O Giles, Che Yiping, Singh Nisha, Forsyth Cecily, Christopherson Richard I, Mulligan Stephen P
Abstract excerpt
Drug resistance in chronic lymphocytic leukemia (CLL) associated with lesions in the ATM/TP53 pathway represents a major challenge in clinical management. Evidence suggests that heat shock protein-90 (Hsp90) inhibitors may represent a therapeutic option in combination with more conventional thera...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.